Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by Benedict16thon May 24, 2020 8:18am
81 Views
Post# 31065982

RE:RE:RE:RE:RE:The Duo...

RE:RE:RE:RE:RE:The Duo...Nozzpack you make very good points thank you. If I may add to your points, there are a many good value companies and paying good dividends with their shares stuck in the mud. You are also finding them in the USA. Currently the market chases and reward new frontiers disruptive innovations companies that replaces the old ways companies.  Value investing has not worked out for a long while. Example: There are ETF that only invest in disruptive innovation companies and they have returned huge profits. The point I have tried to make all along is that GUD has an enviable position of cash while many other companies needs to raise cash all the time. GUD, I have argued needs to bring in young new executive to add a new dimension and perspective of future investing in biotech. The market does not care two beans that GUD has the cash unless. In fact many at times they see it as a negative though I grant that it places a floor for the share price. It is short sighted as there is nothing wrong to bring/add new people with new fresh ideas. Regrettably it has not happened, and I do not understand why?  Every corporation is always looking for the next genius and every Year they add new executives into mngt. I do not have any insight with GUD MNGT nor I want to insult anyone, but someone needs to pass on the message for their own sake and that of the shareholders. Clearly, we all have the option to sell and I may do that after six Years and after I listen to AGM. If they do not add more talent  to MNGT I will be gone.
Here is the link of one of the disruptive innovation ETF ARK. If you subscribe to it, every day after 5 PM they will email you free the trades they made on the day. Very informative for future. investing They do trade a storm.
I do cherry pick on their ideas.  
https://ark-invest.com/
Bullboard Posts